D. Hadler

729 total citations
19 papers, 584 citations indexed

About

D. Hadler is a scholar working on Molecular Biology, Genetics and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, D. Hadler has authored 19 papers receiving a total of 584 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Genetics and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in D. Hadler's work include Coenzyme Q10 studies and effects (5 papers), Hemoglobinopathies and Related Disorders (5 papers) and Mitochondrial Function and Pathology (4 papers). D. Hadler is often cited by papers focused on Coenzyme Q10 studies and effects (5 papers), Hemoglobinopathies and Related Disorders (5 papers) and Mitochondrial Function and Pathology (4 papers). D. Hadler collaborates with scholars based in Germany, Switzerland and Lebanon. D. Hadler's co-authors include Hans Gutzmann, Stefan G. Hofmann, Ralf Ihl, S. Kanowski, W.M. Herrmann, Michael Linden, Michael A. Rapp, Klaus-Peter Kühl, Joachim von Pawel and Martin Reck and has published in prestigious journals such as Blood, Annals of Oncology and Neurobiology of Aging.

In The Last Decade

D. Hadler

19 papers receiving 563 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Hadler Germany 9 210 177 133 111 75 19 584
Pierre Bac France 12 345 1.6× 153 0.9× 87 0.7× 45 0.4× 89 1.2× 32 814
Paul Leber United States 12 312 1.5× 146 0.8× 126 0.9× 184 1.7× 42 0.6× 22 882
Inge‐Britt Lindén Finland 15 261 1.2× 119 0.7× 125 0.9× 113 1.0× 70 0.9× 35 1.2k
William J. Zavadoski United States 14 286 1.4× 165 0.9× 57 0.4× 114 1.0× 77 1.0× 17 700
Christopher D. Aluise United States 12 288 1.4× 309 1.7× 90 0.7× 44 0.4× 24 0.3× 12 852
Tom Thomas United States 10 98 0.5× 212 1.2× 117 0.9× 32 0.3× 33 0.4× 13 525
Mitsugu Hachisu Japan 14 164 0.8× 109 0.6× 113 0.8× 63 0.6× 35 0.5× 59 523
Sonia Gallego‐Sandín Spain 13 227 1.1× 104 0.6× 173 1.3× 50 0.5× 23 0.3× 17 632
Anna Matton Sweden 14 215 1.0× 339 1.9× 136 1.0× 95 0.9× 38 0.5× 40 697
Alessandra Bizzarro Italy 18 216 1.0× 349 2.0× 154 1.2× 204 1.8× 17 0.2× 40 886

Countries citing papers authored by D. Hadler

Since Specialization
Citations

This map shows the geographic impact of D. Hadler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Hadler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Hadler more than expected).

Fields of papers citing papers by D. Hadler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Hadler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Hadler. The network helps show where D. Hadler may publish in the future.

Co-authorship network of co-authors of D. Hadler

This figure shows the co-authorship network connecting the top 25 collaborators of D. Hadler. A scholar is included among the top collaborators of D. Hadler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Hadler. D. Hadler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Boucher, Éveline, Ірина Давиденко, D. Hadler, Reinhard von Roemeling, & Giuseppe Aprile. (2014). A Randomized, Placebo-Controlled, Phase 2 Study of Efatutazone Maintenance Therapy in Patients with Advanced Colorectal Cancer Who Have Achieved Disease Control Following First-Line Chemotherapy. Annals of Oncology. 25. ii8–ii8. 2 indexed citations
2.
3.
Gattermann, Norbert, Mathias Schmid, Carol M. Rose, et al.. (2007). P129 Severe iron overload in patients with myelodysplastic syndromes (MDS) enrolled in a large study of deferasirox (Exjade®, ICL670). Leukemia Research. 31. S109–S110. 7 indexed citations
4.
Taher, Alì, Amal El‐Beshlawy, Abdullah Al Jefri, et al.. (2006). Deferasirox (Exjade®, ICL670) Is Effective and Tolerable in β-Thalassemia Patients with High Iron Burden and History of Inadequate Chelation Therapy.. Blood. 108(11). 3823–3823. 1 indexed citations
5.
6.
Taher, Alì, Amal El‐Beshlawy, Abdullah Al Jefri, et al.. (2005). Deferasirox (Exjade®, ICL670) Treatment of Inadequately Chelated β-Thalassemia Patients from the Middle East: The ESCALATOR Trial.. Blood. 106(11). 3840–3840. 2 indexed citations
7.
Daar, Shahina, Alì Taher, Anil Pathare, et al.. (2005). Plasma LPI in β-Thalassemia Patients before and after Treatment with Deferasirox (Exjade®, ICL670).. Blood. 106(11). 2697–2697. 5 indexed citations
8.
Gutzmann, Hans, Klaus-Peter Kühl, D. Hadler, & Michael A. Rapp. (2002). Safety and Efficacy of Idebenone versus Tacrine in Patients with Alzheimer's Disease: Results of a Randomized, Double-Blind, Parallel-Group Multicenter Study. Pharmacopsychiatry. 35(1). 12–18. 60 indexed citations
9.
Hadler, D., et al.. (2000). Therapeutic Drug Monitoring of Tacrine: Simple and Fast High-Performance Liquid Chromatography Assay Method for Its Determination in Human Plasma. Therapeutic Drug Monitoring. 22(2). 225–229. 1 indexed citations
10.
Gutzmann, Hans & D. Hadler. (1998). Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double-blind multicentre study. Journal of neural transmission. Supplementum. 54. 301–310. 127 indexed citations
11.
Schaffler, K., D. Hadler, & Margaret Stark. (1998). Dose-effect relationship of idebenone in an experimental cerebral deficit model. Pilot study in healthy young volunteers with piracetam as reference drug.. PubMed. 48(7). 720–6. 3 indexed citations
12.
Hadler, D., et al.. (1997). A Controlled Study of 2 Doses of Idebenone in the Treatment of Alzheimer’s Disease. Neuropsychobiology. 36(2). 73–82. 91 indexed citations
13.
Kanowski, S., et al.. (1997). Alzheimer’s Disease Assessment Scale: Reliability and Validity in a Multicenter Clinical Trial. International Psychogeriatrics. 9(2). 123–138. 110 indexed citations
14.
Bodick, N., F. Forette, D. Hadler, et al.. (1997). Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group.. PubMed. 11 Suppl 3. 50–3. 28 indexed citations
15.
Linden, Michael, D. Hadler, & Stefan G. Hofmann. (1997). Randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a new isoindoline derivative (DN-2327) in generalized anxiety. Human Psychopharmacology Clinical and Experimental. 12(5). 445–452. 55 indexed citations
16.
Gutzmann, Hans, H. Erzigkeit, & D. Hadler. (1996). 569 Long-term treatment of Alzheimer's disease with idebenone. Neurobiology of Aging. 17(4). S141–S142. 8 indexed citations
17.
Hadler, D., et al.. (1996). Efficacy and safety of idebenone in the long-term treatment of Alzheimer's Disease: a double-blind, placebo controlled multicentre study. Human Psychopharmacology Clinical and Experimental. 11(1). 53–65. 18 indexed citations
18.
Bussmann, W.‐D., Hans Störger, D. Hadler, et al.. (1987). Long-Term Treatment of Severe Chronic Heart Failure with Captopril. Journal of Cardiovascular Pharmacology. 9. S50–S60. 19 indexed citations
19.
Jungmann, E, Hans Störger, P.-H. Althoff, et al.. (1985). Aldosterone and prolactin responsiveness after prolonged treatment of congestive heart failure with captopril. European Journal of Clinical Pharmacology. 28(1). 1–4. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pierre Bac Breakdown of academic impact, for papers by Paul Leber Breakdown of academic impact, for papers by Inge‐Britt Lindén Breakdown of academic impact, for papers by William J. Zavadoski Breakdown of academic impact, for papers by Christopher D. Aluise Breakdown of academic impact, for papers by Tom Thomas Breakdown of academic impact, for papers by Mitsugu Hachisu Breakdown of academic impact, for papers by Sonia Gallego‐Sandín Breakdown of academic impact, for papers by Anna Matton Breakdown of academic impact, for papers by Alessandra Bizzarro
Rankless by CCL
2026